AstraZeneca Says It May Consider Exposing Vaccine Trial Participants to Virus AstraZeneca Says It May Consider Exposing Vaccine Trial Participants to Virus
The chief executive of AstraZeneca, which is developing a leading coronavirus vaccine with Oxford University, said it is too early to deliberately expose vaccine trial participants to the pathogen, but it may become an option if ongoing trials hit a snag.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - May 29, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

AstraZeneca, Daiichi niche drug shows promise beyond breast cancer
AstraZeneca and Daiichi Sankyo's Enhertu helped patients with three different types of cancer live longer in trials, pointing to potential broader use of the breast cancer treatment. (Source: Reuters: Health)
Source: Reuters: Health - May 29, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Genestack signs multi-year agreement with AstraZeneca to implement Omics Data Manager
(Genestack Ltd) Genestack Ltd. today announced that its flagship multi-omics data catalogue, curation and integrative search product, Omics Data Manager (ODM), has been licensed and implemented by AstraZeneca. Genestack's ODM is an enabling technology providing a central hub for organizing and querying multi-omics data from multiple sites, including transcriptomics and proteomics. ODM provides mission-critical technology modules that enable life science enterprises to execute their data strategy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2020 Category: International Medicine & Public Health Source Type: news

AstraZeneca's top-selling drug slows early-stage lung cancer - trial
AstraZeneca's top-selling drug Tagrisso has been shown to hold back a certain type of lung cancer when diagnosed at an early stage, the British drugmaker said on Thursday, potentially adding billions to its sales potential. (Source: Reuters: Health)
Source: Reuters: Health - May 28, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca picks Oxford Biomedica to make potential COVID-19 vaccine
AstraZeneca has partnered with British cell therapy company Oxford Biomedica to make its experimental COVID-19 vaccine as the drugmaker looks to bolster its manufacturing capacity to produce one billion doses. (Source: Reuters: Health)
Source: Reuters: Health - May 28, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Durvalumab Phase III Trial Could Change Mesothelioma Care
An international, much-anticipated phase III clinical trial that could change standard-of-care treatment for patients with malignant pleural mesothelioma will open soon, pending COVID-19 pandemic restrictions. The randomized trial will be studying the effectiveness of the immunotherapy drug durvalumab (Imfinzi) when used in combination with chemotherapy drugs pemetrexed (Alimta) and cisplatin for mesothelioma. Opening dates may vary by center because of the COVID-19 pandemic that has slowed or stalled clinical trials everywhere. Durvalumab produces an antibody that helps a patient’s own immune system kill tumor cell...
Source: Asbestos and Mesothelioma News - May 28, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

The lessons and consequences of a failed megadeal
For executives browsing DD, there are lessons to learn from the Pfizer/AstraZeneca saga (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 28, 2020 Category: Pharmaceuticals Source Type: news

Drug wars: how AstraZeneca overtook GSK in UK pharma
With new cancer drugs and a vaccines partnership with Oxford university, AZ’s turnround has boosted the industry in Britain (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 27, 2020 Category: Pharmaceuticals Source Type: news

FDA clears Propeller Health sensor for use with AstraZeneca's Symbicort inhaler
The digital respiratory health company says this deal and clearance now give it access to 90% of the U.S. asthma and COPD market. (Source: mobihealthnews)
Source: mobihealthnews - May 26, 2020 Category: Information Technology Source Type: news

ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
AstraZeneca to Leverage ArcherDX's PCM Liquid Biopsy Technology to Facilitate Multiple Clinical Trials for Early-Stage Non-Small Cell Lung Cancer Therapies BOULDER, Colo., May 26, 2020 -- (Healthcare Sales & Marketing Network) -- ArcherDX, Inc., today ... Biopharmaceuticals, Diagnostics, Oncology ArcherDX, AstraZeneca, Anchored Multiplex PCR, Personalized Cancer Monitoring (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 26, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca ready to vaccinate half of Great Britain for coronavirus by SEPTEMBER
(Natural News) Where will the first vaccines for the Wuhan coronavirus (COVID-19) be unleashed? In Great Britain, assuming a scheme hatched by the British government to vaccinate half the population by September is a success. Reports indicate that drug giant AstraZeneca has been contracted by the United Kingdom to turn an experimental Wuhan coronavirus (COVID-19)... (Source: NaturalNews.com)
Source: NaturalNews.com - May 24, 2020 Category: Consumer Health News Source Type: news

Human trials of British coronavirus vaccine to reach 10,000
Oxford University and AstraZeneca are recruiting around 10,000 adults and children in Britain for trials of an experimental coronavirus vaccine, a day after receiving U.S. backing worth up to $1.2 billion. (Source: Reuters: Health)
Source: Reuters: Health - May 22, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

U.S. Offers $1.2 Billion to Drug Company for COVID-19 Vaccine Research
FRIDAY, May 22, 2020 -- The U.S. Department of Health and Human Services said Thursday it would provide up to $1.2 billion to AstraZeneca to develop a potential COVID-19 vaccine from a lab in Oxford, England. The fourth, and largest, vaccine... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 22, 2020 Category: Pharmaceuticals Source Type: news

U.S. Offers & #36;1.2 Billion to Drug Company for COVID-19 Vaccine Research
FRIDAY, May 22, 2020 -- The U.S. Department of Health and Human Services said Thursday it would provide up to $1.2 billion to AstraZeneca to develop a potential COVID-19 vaccine from a lab in Oxford, England. The fourth, and largest, vaccine... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 22, 2020 Category: Pharmaceuticals Source Type: news

U.K. COVID-19 Study Aims to Immunize More Than 10,000 with Experimental Vaccine
(London) — British researchers testing an experimental vaccine against the new coronavirus are moving into advanced studies and aim to immunize more than 10,000 people to determine if the shot works. Last month, scientists at Oxford University began vaccinating more than 1,000 volunteers in a preliminary study designed to test the shot’s safety. Those results aren’t in yet but on Friday, the scientists announced they’re expanding to 10,260 people across Britain, including older people and children. If all goes smoothly, “it’s possible as early as the autumn or toward the end of the year,...
Source: TIME: Health - May 22, 2020 Category: Consumer Health News Authors: aria Cheng and Lauran Neergaard / AP Tags: Uncategorized COVID-19 News Desk wire Source Type: news

U.S. Earmarks $1.2 Billion for New Vaccine Deal as Coronavirus Deaths Near 95,000
FRIDAY, May 22, 2020 -- The U.S. Department of Health and Human Services said Thursday it would provide up to $1.2 billion to the drug company AstraZeneca to develop a potential coronavirus vaccine from a lab in Oxford, U.K. The fourth, and largest,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 22, 2020 Category: General Medicine Source Type: news

AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine
AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford's vaccine widely accessible around the world in an equitable manner. (Source: World Pharma News)
Source: World Pharma News - May 22, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

$1.2 Billion From U.S. to Drugmaker to Pursue Coronavirus Vaccine
The Trump administration announced a grant to AstraZeneca, which has licensed a potential vaccine that is in trials by Oxford University. (Source: NYT Health)
Source: NYT Health - May 22, 2020 Category: Consumer Health News Authors: David D. Kirkpatrick Tags: Vaccination and Immunization Coronavirus (2019-nCoV) Research Clinical Trials Drugs (Pharmaceuticals) AstraZeneca PLC Biomedical Advanced Research and Development Authority Health and Human Services Department your-feed-healthcare Source Type: news

AstraZeneca CEO on progress towards a coronavirus vaccine
Pascal Soriot, CEO of the pharmaceutical company AstraZeneca, says he thinks "there ’s a good chance" the coronavirus vaccine they're working on with the University of Oxford will be successful. He spoke with CBS News' Charlie D'Agata about efforts to get a vaccine to the public in record time. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - May 21, 2020 Category: Consumer Health News Source Type: news

US Secures 300 Million Doses of Potential AstraZeneca COVID-19 Vaccine US Secures 300 Million Doses of Potential AstraZeneca COVID-19 Vaccine
The United States has secured almost a third of the first one billion doses planned for AstraZeneca's experimental COVID-19 vaccine by pledging up to $1.2 billion, as world powers scramble for medicines to get their economies back to work.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 21, 2020 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Covid-19 has brought on a case of corporate good citizenship at AstraZeneca
Drugmaker is not a vaccine specialist but investing in that area has benefits (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 21, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca CEO says $1 billion vaccine bet is 'absolutely worth it'
AstraZeneca's CEO says the US government's $1 billion investment in its coronavirus vaccine is a gamble -- but worth the risk. (Source: CNN.com - Health)
Source: CNN.com - Health - May 21, 2020 Category: Consumer Health News Source Type: news

U.S. secures 300 million doses of potential AstraZeneca COVID-19 vaccine
The United States has secured almost a third of the first one billion doses planned for AstraZeneca's experimental COVID-19 vaccine by pledging up to $1.2 billion, as world powers scramble for medicines to get their economies back to work. (Source: Reuters: Health)
Source: Reuters: Health - May 21, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca secures orders for virus vaccine under testing
Drug maker AstraZeneca has secured the first agreements Thursday for 400 million doses of a COVID-19 vaccine that is being trialed (Source: ABC News: Health)
Source: ABC News: Health - May 21, 2020 Category: Consumer Health News Tags: Health Source Type: news

AstraZeneca could supply potential coronavirus vaccine from September
Firm has capacity to make 1bn doses of Oxford University drug undergoing trialsCoronavirus – latest updatesSee all our coronavirus coverageAstraZeneca has said it has the capacity to manufacture 1bn doses of the University of Oxford ’s potential Covid-19 vaccine and will begin supply in September if clinicaltrialsare successful.The Anglo-Swedish drugmaker said it had signed the first agreements to supply at least 400m doses of the potential vaccine, yet to be proven effective, which it isdeveloping withthe university. AstraZeneca said it recognised the vaccine might not work but if results from the early stage ...
Source: Guardian Unlimited Science - May 21, 2020 Category: Science Authors: Staff and agencies Tags: Pharmaceuticals industry AstraZeneca Coronavirus outbreak Vaccines and immunisation University of Oxford UK news Business Health Science Source Type: news

U.S. orders 300 million doses of potential COVID-19 vaccine
The U.S. government has ordered 300 million doses of a potential COVID-19 virus being developed by AstraZeneca and Oxford University and hopes first doses can be made available by October, the Department of Health and Human Services said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - May 21, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca books orders for 400m doses of Oxford vaccine
Drugmaker also secures $1bn in funding from US government to aid development (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 21, 2020 Category: Pharmaceuticals Source Type: news

AstraZeneca-Merck's Lynparza gets U.S. FDA nod for prostate cancer treatment
The U.S. Food and Drug Administration approved AstraZeneca Plc and Merck& Co Inc's Lynparza as a treatment for a form of prostate cancer, the companies said in a joint statement on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - May 20, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Lynparza Approved in the US for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
20 May 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck& Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been approved in the US for patients with homologous recombination repair (HRR)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 20, 2020 Category: Drugs & Pharmacology Source Type: news

First human trial results raise hopes for coronavirus vaccine
Eight initial volunteers in US produced an antibody response from Moderna ’s RNA vaccineCoronavirus – latest updatesSee all our coronavirus coverageThe first results from human trials of a vaccine against Covid-19 have given a glimmer of hope after a US firm ’s study produced positive results in a group of eight volunteers.These results – which come a day after the UK government revealeda deal to secure 30m dosesof a rival Oxford University vaccine, should it be successful – showed that each of the participants produced an antibody response on a par with that seen in people who have had the di...
Source: Guardian Unlimited Science - May 18, 2020 Category: Science Authors: Sarah Boseley Health editor Tags: Vaccines and immunisation Coronavirus outbreak Infectious diseases Medical research Science AstraZeneca Source Type: news

Britain's £130 million plan to manufacture a coronavirus vaccine
Britain will get first access to a coronavirus vaccine being developed by Oxford University with pharmaceutical giant AstraZeneca poised to make 30 million for the UK by September - if it works. (Source: the Mail online | Health)
Source: the Mail online | Health - May 18, 2020 Category: Consumer Health News Source Type: news

A Vaccine Against COVID-19 Would Be the Latest Success in a Long Scientific History
Here’s betting you wouldn’t want anyone blowing smallpox scabs up your nose. But you might feel differently if you lived in 15th century China. Long ago, the Chinese recognized that people who had contracted smallpox once were immune to reinfection. They came up with the idea of preserving scabs from individuals who had suffered mild cases, drying them out, crushing them to a powder and blowing them up the nostril. For boys it was the right nostril, for girls it was the left because, well, 15th century. That is how the story of vaccines usually begins, though that version is decidedly incomplete. For one thing,...
Source: TIME: Science - May 15, 2020 Category: Science Authors: Jeffrey Kluger Tags: Uncategorized COVID-19 Explainer health Source Type: news

Lynparza (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
KENILWORTH, N.J.--(BUSINESS WIRE)--May 8, 2020 -- AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Lynparza in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 8, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Dapagliflozin (Farxiga) for Low-EF Heart Failure FDA Approves Dapagliflozin (Farxiga) for Low-EF Heart Failure
The widely anticipated approval makes dapagliflozin (Farxiga, AstraZeneca) the only drug in its class to be indicated for heart failure in the absence of diabetes.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 6, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Farxiga Approved in the US for the Treatment of Heart Failure in Patients with Heart Failure with Reduced Ejection Fraction
6 May 2020 -- AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 6, 2020 Category: Drugs & Pharmacology Source Type: news

The promise of an Oxford vaccine reveals how a new Britain could thrive | Will Hutton
The partnership between AstraZeneca and the Jenner Institute should jolt our industry and banksCoronavirus latest updatesSee all our coronavirus coverageThere was some good news last week. Oxford University ’s Jenner Institute announced it wasteaming up with AstraZeneca to take a promising prototype of coronavirus vaccine into volume production by the autumn. Of course there are caveats – the institute’sconfidence in its vaccine may not be validated by the trials that began last week.Still it was heartening, after so much tragic incompetence, that a British university and a British company could forge a r...
Source: Guardian Unlimited Science - May 3, 2020 Category: Science Authors: Will Hutton Tags: Coronavirus outbreak Infectious diseases Medical research Microbiology Science AstraZeneca University of Oxford Pharmaceuticals industry Banking Business UK news Source Type: news

Coronavirus means science is suddenly being done differently – and so is politics | Paul Nurse
The Nobel prize-winning scientist on how the pandemic is bringing dramatic shifts in medical researchSee all our coronavirus coverageCoronavirus – latest updatesIf we are to return to our normal lives, we need answers to many questions and they will only be delivered by science and medicine and their applications. In fact, the speed with which the virus has spread around the globe has been matched by the speed with which many scientists have mobilised themselves to take on this pandemic.The British science community has responded rapidly. The government ’s funding agency, UK Research and Innovation-Medical Rese...
Source: Guardian Unlimited Science - May 2, 2020 Category: Science Authors: Paul Nurse Tags: Medical research Coronavirus outbreak Infectious diseases Microbiology Science Vaccines and immunisation GlaxoSmithKline AstraZeneca Health Source Type: news

New Study of Diabetes Drug for COVID-19 Raises Eyebrows
Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19. (Source: WebMD Health)
Source: WebMD Health - May 1, 2020 Category: Consumer Health News Source Type: news

New Study of Diabetes Drug for COVID-19 Raises Eyebrows New Study of Diabetes Drug for COVID-19 Raises Eyebrows
Some question the safety of AstraZeneca's just-launched DARE-19 study testing whether the type 2 diabetes drug dapagliflozin will reduce adverse outcomes of COVID-19.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 30, 2020 Category: Infectious Diseases Tags: Diabetes & Endocrinology News Source Type: news

AstraZeneca teams up with Oxford University to develop COVID-19 vaccine
Britain's AstraZeneca joined forces with the University of Oxford on Thursday to help develop, produce and distribute a potential COVID-19 vaccine, as drugmakers around the world race to find a solution to the deadly disease. (Source: Reuters: Health)
Source: Reuters: Health - April 30, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca strikes deal with Oxford University to mass produce experimental COVID-19 vaccine
Human trials of the ChAdOx1 nCoV-19 vaccine developed by Oxford University's Jenner Institute began last week, with hundreds of people volunteering to be part of the study. (Source: the Mail online | Health)
Source: the Mail online | Health - April 30, 2020 Category: Consumer Health News Source Type: news

AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2. The collaboration aims to bring to patients the potential vaccine known as ChAdOx1 nCoV-19, being developed by the Jenner Institute and Oxford Vaccine Group, at the University of Oxford. (Source: World Pharma News)
Source: World Pharma News - April 30, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AstraZeneca and Oxford university agree deal to develop virus vaccine
Partnership that would prioritise UK could produce 100m doses by year-end if treatment is effective (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - April 30, 2020 Category: Pharmaceuticals Source Type: news

Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in Covid-19 patients. The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 25, 2020 Category: Pharmaceuticals Authors: Brian Kaberline Source Type: news

Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious Covid-19 complications
Saint Luke's Mid America Heart Institute and drug company AstraZeneca PLC are conducting a clinical trial to see if a drug now used to treat diabetes could help prevent deadly complications in Covid-19 patients. The DARE-19 trial involves dapagliflozin, which is marketed in the United States as Farxiga and can reduce blood glucose levels in diabetes patients. The double-blind trial follows previous research indicating that the drug also may provide some protection to the heart and kidney for high-risk… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 25, 2020 Category: Biotechnology Authors: Brian Kaberline Source Type: news

AstraZeneca pilots diabetes drug as potential COVID-19 treatment
Britain's AstraZeneca is testing a diabetes drug as a potential treatment for COVID-19 patients who also had existing heart and kidney problems, its second trial of an approved therapy to help treat the disease caused by the coronavirus. (Source: Reuters: Health)
Source: Reuters: Health - April 23, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

AstraZeneca and Saint Luke ’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients
AstraZeneca and Saint Luke's Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients hospitalised with COVID-19 who are at risk of developing serious complications, such as organ failure. (Source: World Pharma News)
Source: World Pharma News - April 23, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Customer centricity in a changed world
  Few or no reps on the road, patients confined en masse to their homes and a healthcare and economic emergency of which we can still only guess the scale and duration.    It is a situation that pharma ’s marketing folk never expected, never planned for and one which our panel discuss in depth on day one of eyeforpharma’s Philadelphia Virtual conference in the panel session on customer centricity. Marketing departments face a daunting challenge. More used to planning for slowly emerging trends, they are being forced by the pandemic situation to react in real time to increase their digital ...
Source: EyeForPharma - April 20, 2020 Category: Pharmaceuticals Authors: Andrew Stone Source Type: news

New UK taskforce to help develop and roll out coronavirus vaccine
Government bodies, industry and charities including AstraZeneca and Wellcome Trust to collaborate in coordinating effortsCoronavirus – latest updatesSee all our coronavirus coverageCoronavirus vaccine – when will we have one?The government has announced a new vaccines taskforce to help the development of a vaccine for Covid-19 and ensure its rapid production and rollout if one arrives.The business secretary, Alok Sharma, also gave details of cash grants for work into both vaccines and potential treatments. Among the projects receiving cash is one led by Public Health England which hopes to develop an antibody d...
Source: Guardian Unlimited Science - April 17, 2020 Category: Science Authors: Peter Walker and Hannah Devlin Tags: Coronavirus outbreak Vaccines and immunisation Alok Sharma UK news Health Politics Science Source Type: news

AstraZeneca Announces CALAVI Trial to Examine Acalabrutinib for Patients with COVID-19
AstraZeneca announced it will be conducting a global clinical trial, CALAVI, to examine the impact of adding acalabrutinib to best supportive care for patients who are severely ill with the COVID-19 infection. (Source: CancerNetwork)
Source: CancerNetwork - April 15, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news